Literature DB >> 8930062

Ring chromosome 22 and mood disorders.

R Sovner1, A Stone, C Fox.   

Abstract

The case of a 21-year-old man with severe developmental disabilities, ring chromosome 22 and rapid-cycling bipolar illness is presented. This is the first reported occurrence of mood disorder in a person with ring chromosome 22. Previously published case reports describing behavioural problems associated with this chromosome disorder suggest that severe hyperactivity is typical and that affected individuals may have an excited mood state. These symptoms are consistent with atypical bipolar disorder and raise the possibility that ring chromosome 22 increases the risk for atypical bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930062     DOI: 10.1111/j.1365-2788.1996.tb00607.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  4 in total

1.  Neuropsychopathology in 7 Patients with the 22q13 Deletion Syndrome: Presence of Bipolar Disorder and Progressive Loss of Skills.

Authors:  A Denayer; H Van Esch; T de Ravel; J-P Frijns; G Van Buggenhout; A Vogels; K Devriendt; J Geutjens; P Thiry; A Swillen
Journal:  Mol Syndromol       Date:  2012-05-16

2.  Ring chromosome 22: a review of the literature and first report from India.

Authors:  S Mahajan; A Kaur; J Singh
Journal:  Balkan J Med Genet       Date:  2012-06       Impact factor: 0.519

3.  Reduced Efficacy of d-Amphetamine and 3,4-Methylenedioxymethamphetamine in Inducing Hyperactivity in Mice Lacking the Postsynaptic Scaffolding Protein SHANK1.

Authors:  A Özge Sungur; Tobias M Redecker; Elena Andres; Wiebke Dürichen; Rainer K W Schwarting; Adriana Del Rey; Markus Wöhr
Journal:  Front Mol Neurosci       Date:  2018-11-16       Impact factor: 5.639

4.  Neuropsychiatric decompensation in adolescents and adults with Phelan-McDermid syndrome: a systematic review of the literature.

Authors:  Alexander Kolevzon; Elsa Delaby; Elizabeth Berry-Kravis; Joseph D Buxbaum; Catalina Betancur
Journal:  Mol Autism       Date:  2019-12-24       Impact factor: 7.509

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.